Forte Biosciences (FBRX) News Today

Forte Biosciences, Inc. (NASDAQ: FBRX) shares have moved sharply higher and remain near the proposed $77-per-share cash acquisition price after argenx SE agreed to acquire the company for approximately $2.2 billion. The transaction represents roughly a 41% premium to Forte’s prior closing price and is the primary catalyst behind the stock’s surge.

• Positive Sentiment: argenx will acquire all outstanding Forte shares for $77 in cash, giving investors a clear deal-value reference and significantly repricing FBRX above its pre-announcement level. The acquisition also gives argenx access to Forte’s experimental autoimmune therapy FB102, strengthening its immunology pipeline. Reuters article
• Positive Sentiment: The all-cash structure reduces exposure to biotechnology development risk for Forte shareholders, while the premium and strategic interest from argenx provide support for the current valuation. Proactive Investors article
• Neutral Sentiment: FBRX trading volume has been substantially above its average, consistent with merger-related positioning. A significant increase in put-option activity also indicates that some traders are hedging against deal or market risk rather than simply betting on further gains.
• Negative Sentiment: Several shareholder-rights law firms, including Kahn Swick & Foti, are investigating whether the $77 consideration and sale process adequately protect shareholders. Similar investigations by Halper Sadeh, Ademi and Monteverde could create litigation, delay or renegotiation risk, although these announcements do not by themselves indicate that the transaction will fail. Kahn Swick & Foti investigation

With FBRX close to the $77 offer price, further upside is likely limited unless a competing bid emerges. Investors are primarily assessing the probability and timing of closing, regulatory or shareholder challenges, and the possibility of a higher offer.